查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2030 年北美传染病治疗市场预测 - 区域分析 - 按药物类别、适应症、给药途径和配销通路
市场调查报告书
商品编码
1562248

2030 年北美传染病治疗市场预测 - 区域分析 - 按药物类别、适应症、给药途径和配销通路

North America Infectious Disease Therapeutics Market Forecast to 2030 - Regional Analysis - by Drug Class, Indication, Route Of Administration, and Distribution Channel
出版日期: | 出版商: The Insight Partners | 英文 100 Pages | 订单完成后即时交付

价格

2022年北美传染病治疗市值为463.7653亿美元，预计到2030年将达到659.5597亿美元；预计2022年至2030年复合年增长率为4.5%。

传染病发生率上升推动北美传染病治疗市场

传染病是由病毒、寄生虫、细菌、真菌、有毒产物和其他传染源引起的。爱滋病毒是全世界的重大公共卫生议题。根据联合国爱滋病毒/爱滋病联合规划署 (UNAIDS) 的数据，2020 年，约有 3,770 万人感染爱滋病毒。其中，3600万是成年人，170万是0-14岁的儿童。此外，超过一半（53%）是女孩和妇女。此外，2020 年全球报告了 150 万新的爱滋病毒病例。同样，肝炎是由病毒感染引起的肝臟感染。肝炎病毒的主要类型为甲型、乙型、丙型、丁型和戊型 根据世界卫生组织(WHO) 统计，全球约有5,800 万人患有慢性丙型肝炎病毒感染，每年约有150 万人患有慢性丙型肝炎病毒感染。

据世界卫生组织称，结核病 (TB) 是全球第 13 大死亡原因，也是仅次于 COVID-19 的第二大传染病。 2020 年，结核病导致 150 万人死亡（其中 214,000 人感染爱滋病毒）。此外，2020年全球有1,000万人患有结核病，其中包括110万名儿童、330万名女性和560万男性。此外，医院获得性感染或医疗保健相关感染（HAI）的发生率和死亡率很高。此外，每年医疗保健系统的支出也是巨大的。美国疾病管制与预防中心 (CDC) 报告称，医院感染每年在美国医院造成约 170 万例感染病例和 99,000 例死亡。因此，全球传染病率的上升推动了传染病治疗市场的成长。

北美传染病治疗市场概况

北美的传染病治疗市场分为美国、加拿大和墨西哥。到 2022 年，北美将占据全球市场的最大份额。此外，大型医疗保健企业以及对治疗慢性病和病毒性疾病的先进治疗解决方案不断增长的需求正在推动该地区的市场扩张。由于抗病毒疗法的日益采用，对抗病毒药物的需求不断增长，预计将推动美国市场的发展。主要医药和生物製药公司致力于扩大其抗病毒药物的生产能力。例如，加州吉利德科学公司(Gilead Sciences, Inc.) 于2020 年5 月获得FDA 批准用于治疗COVID-19 的研究性抗病毒药物瑞德西韦(Remdesivir)。管理局(FDA) 于2022 年4 月批准了一种补充新药吉利德科学公司的Veklury（瑞德西韦）申请（sNDA）用于治疗年龄超过28 天、体重至少3 公斤、因COVID-19 住院治疗或患有轻度至中度COVID-19 感染的儿科患者。 2021 年 9 月，拜登-哈里斯政府透过疾病管制与预防中心 (CDC) 投资 21 亿美元，以改善全国公共卫生和医疗保健部门的感染控制和预防活动。预计这些因素将在预测期内推动美国传染病治疗市场的成长。

北美传染病治疗市场收入及 2030 年预测（百万美元）

北美传染病治疗市场细分

北美传染病治疗市场按药物类别、适应症、给药途径、配销通路和国家分类。

依药物类别，北美传染病治疗市场分为抗病毒、抗菌、抗真菌等。 2022 年，抗病毒药物领域占据最大的市场份额。

从适应症来看，北美传染病治疗市场分为爱滋病毒、肝炎、结核病、流感、HPV等。 2022 年，HIV 占据最大的市场份额。

依给药途径，北美传染病治疗市场分为口服、肠胃外、外用等。 2022 年，口腔细分市场占据最大的市场份额。

从配销通路来看，北美传染病治疗市场分为医院药局、零售药局等。 2022年，医院药局占最大的市场份额。

依国家/地区划分，北美传染病治疗市场分为美国、加拿大和墨西哥。 2022年，美国在北美传染病治疗市场占有率中占据主导地位。

AbbVie Inc、Astellas Pharma Inc、Bayer AG、BioCryst Pharmaceuticals Inc、F. Hoffmann-La Roche Ltd、Gilead Sciences Inc、GSK Plc、Merck & Co Inc、Pfizer Inc 和 Shionogi & Co Ltd 是在北美传染病治疗市场。

目录

第 1 章：简介

第 2 章：执行摘要

  • 主要见解

第 3 章：研究方法

  • 覆盖范围
  • 二次研究
  • 初步研究

第 4 章：北美传染病治疗市场 - 主要市场动态

  • 北美传染病治疗市场 - 主要市场动态
  • 市场驱动因素
    • 传染病病率上升
    • 越来越关注传染病治疗的经费与研发
  • 市场限制
    • 抗感染药物抗药性的出现及相关副作用
  • 市场机会
    • 发展中国家不断成长的机会
    • 抗生素抗药性威胁不断升级
  • 未来趋势
    • 产品批准和发布数量不断增加
  • 驱动因素和限制的影响：

第 5 章：传染病治疗市场 - 北美市场分析

  • 北美传染病治疗市场收入，2022-2030

第 6 章：北美传染病治疗市场分析 - 按药物类别

  • 概述
  • 抗病毒剂
  • 抗菌
  • 抗真菌
  • 其他的

第 7 章：北美传染病治疗市场分析 - 按适应症

  • 概述
  • 爱滋病
  • 肝炎
  • 结核
  • 流感
  • HPV病毒
  • 其他的

第 8 章：北美传染病治疗市场分析 - 按给药途径

  • 概述
  • 口服
  • 注射用
  • 专题
  • 其他的

第 9 章：北美传染病治疗市场分析 - 按配销通路

  • 概述
  • 医院药房
  • 零售药局
  • 其他的

第 10 章：北美传染病治疗市场 - 国家分析

  • 美国
  • 加拿大
  • 墨西哥

第 11 章：传染病治疗市场-产业格局

  • 概述
  • 传染病治疗市场的成长策略
  • 无机成长策略
    • 概述
  • 有机成长策略
    • 概述

第 12 章：公司简介

  • Pfizer Inc
  • Gilead Sciences Inc
  • F. Hoffmann-La Roche Ltd
  • Shionogi & Co Ltd
  • Bayer AG
  • BioCryst Pharmaceuticals Inc
  • GSK Plc
  • AbbVie Inc
  • Merck & Co Inc
  • Astellas Pharma Inc

第 13 章：附录

Product Code: BMIRE00030503

The North America infectious disease therapeutics market was valued at US$ 46,376.53 million in 2022 and is expected to reach US$ 65,955.97 million by 2030; it is estimated to register a CAGR of 4.5% from 2022 to 2030.

Rising Prevalence of Infectious Disease Fuels North America Infectious Disease Therapeutics Market

Infectious diseases are caused by viruses, parasites, bacteria, fungi, toxic products, and other infectious agents. HIV is a major public health issue across the world. According to The Joint United Nations Programme on HIV/AIDS (UNAIDS), in 2020, ~ 37.7 million people had HIV. Out of these, 36 million were adults, and 1.7 million were children aged 0-14 years. Also, more than half (53%) were girls and women. Moreover, 1.5 million new HIV cases were reported in 2020 globally. Similarly, hepatitis is an infection of the liver caused by a viral infection. The main types of hepatitis viruses are A, B, C, D, and E. According to the World Health Organization (WHO), globally, ~ 58 million people are suffering from chronic hepatitis C virus infection, and every year, ~1.5 million new infections occur.

According to WHO, tuberculosis (TB) is the 13th top cause of death globally and the second leading infectious disease after COVID-19. In 2020, 1.5 million deaths were caused by TB (including 214,000 people affected by HIV). Furthermore, 10 million people had TB globally in 2020, including 1.1 million children, 3.3 million women, and 5.6 million men. Moreover, hospital-acquired infections or healthcare-associated infections (HAIs) have a high morbidity and mortality rate. Also, the expenditure on the healthcare system is huge every year. The Centers for Disease Control and Prevention (CDC) reported that HAIs account for ~1.7 million infection cases and 99,000 deaths every year in American hospitals. Therefore, the rising prevalence of infectious diseases across the globe drives the growth of the infectious disease therapeutics market.

North America Infectious Disease Therapeutics Market Overview

The infectious disease therapeutics market in North America is segmented into the US, Canada, and Mexico. North America accounted for the largest share of the global market in 2022. Growing adoption of technological advancements and rising research and development activities are projected to accelerate the growth of the infectious disease therapeutics market. Moreover, large healthcare businesses and the rising demand for advanced therapeutic solutions to treat chronic conditions and viral diseases are propelling the market expansion in this region. The burgeoning demand for antiviral agents due to the growing adoption of antiviral therapies is anticipated to drive the market in the US. Major medicine and biopharmaceutical companies focus on expanding their antiviral agent manufacturing capacities. For instance, Gilead Sciences, Inc., California, received FDA approval for its investigational antiviral-Remdesivir-to treat COVID-19 in May 2020. Additionally, in April 2022, the US Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) of Gilead Sciences for Veklury (remdesivir) for the treatment of pediatric patients above 28 days, weighing at least 3 kg, and are hospitalized for COVID-19 treatment or have mild-to-moderate COVID-19 infection. In September 2021, the Biden-Harris Administration invested US$ 2.1 billion through the Centers for Disease Control and Prevention (CDC) to improve infection control and prevention activities across the country's public health and healthcare sectors. These factors are anticipated to boost the US infectious disease therapeutics market growth during the forecast period.

North America Infectious Disease Therapeutics Market Revenue and Forecast to 2030 (US$ Million)

North America Infectious Disease Therapeutics Market Segmentation

The North America infectious disease therapeutics market is categorized into drug class, indication, route of administration, distribution channel, and country.

Based on drug class, the North America infectious disease therapeutics market is segmented into anti-viral, anti-bacterial, anti-fungal, and others. The anti-viral segment held the largest market share in 2022.

In terms of indication, the North America infectious disease therapeutics market is segmented into HIV, hepatitis, tuberculosis, influenza, HPV, and others. The HIV held the largest market share in 2022.

Based on route of administration, the North America infectious disease therapeutics market is segmented into oral, parenteral, topical, and others. The oral segment held the largest market share in 2022.

In terms of distribution channel, the North America infectious disease therapeutics market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies held the largest market share in 2022.

By country, the North America infectious disease therapeutics market is segmented into the US, Canada, and Mexico. The US dominated the North America infectious disease therapeutics market share in 2022.

AbbVie Inc, Astellas Pharma Inc, Bayer AG, BioCryst Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, GSK Plc , Merck & Co Inc, Pfizer Inc, and Shionogi & Co Ltd are some of the leading companies operating in the North America infectious disease therapeutics market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. North America Infectious Disease Therapeutics Market - Key Market Dynamics

  • 4.1 North America Infectious Disease Therapeutics Market - Key Market Dynamics
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Infectious Disease
    • 4.2.2 Increasing Focus on Funding and R&D in Infectious Disease Therapeutics
  • 4.3 Market Restraints
    • 4.3.1 Emergence of Anti-infective Drugs Resistance and Associated Side Effects
  • 4.4 Market Opportunities
    • 4.4.1 Growing Opportunities in Developing Nations
    • 4.4.2 Escalating Threat of Antibiotic Resistance
  • 4.5 Future Trends
    • 4.5.1 Rising Number of Product Approvals and Launches
  • 4.6 Impact of Drivers and Restraints:

5. Infectious Disease Therapeutics Market - North America Market Analysis

  • 5.1 North America Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030

6. North America Infectious Disease Therapeutics Market Analysis - by Drug Class

  • 6.1 Overview
  • 6.2 Anti-Viral
    • 6.2.1 Overview
    • 6.2.2 Anti-viral: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.3 Anti-bacterial
    • 6.3.1 Overview
    • 6.3.2 Anti-bacterial: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.4 Anti-fungal
    • 6.4.1 Overview
    • 6.4.2 Anti-fungal: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.5 Others
    • 6.5.1 Overview
    • 6.5.2 Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

7. North America Infectious Disease Therapeutics Market Analysis - by Indication

  • 7.1 Overview
  • 7.2 HIV
    • 7.2.1 Overview
    • 7.2.2 HIV: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.3 Hepatitis
    • 7.3.1 Overview
    • 7.3.2 Hepatitis: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Tuberculosis
    • 7.4.1 Overview
    • 7.4.2 Tuberculosis: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5 Influenza
    • 7.5.1 Overview
    • 7.5.2 Influenza: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.6 HPV
    • 7.6.1 Overview
    • 7.6.2 HPV: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.7 Others
    • 7.7.1 Overview
    • 7.7.2 Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Infectious Disease Therapeutics Market Analysis - by Route of Administration

  • 8.1 Overview
  • 8.2 Oral
    • 8.2.1 Overview
    • 8.2.2 Oral: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.3 Parenteral
    • 8.3.1 Overview
    • 8.3.2 Parenteral: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Topical
    • 8.4.1 Overview
    • 8.4.2 Topical: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.5 Others
    • 8.5.1 Overview
    • 8.5.2 Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

9. North America Infectious Disease Therapeutics Market Analysis - by Distribution Channel

  • 9.1 Overview
  • 9.2 Hospital Pharmacies
    • 9.2.1 Overview
    • 9.2.2 Hospital Pharmacies: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.3 Retail Pharmacies
    • 9.3.1 Overview
    • 9.3.2 Retail Pharmacies: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.4 Others
    • 9.4.1 Overview
    • 9.4.2 Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

10. North America Infectious Disease Therapeutics Market - Country Analysis

  • 10.1 North America Infectious Disease Therapeutics Market Overview
    • 10.1.1 North America Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
      • 10.1.1.1 North America Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
      • 10.1.1.2 United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.2.1 Overview
      • 10.1.1.3 United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.3.1 United States: Infectious Disease Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.3.2 United States: Infectious Disease Therapeutics Market Breakdown, by Indication
        • 10.1.1.3.3 United States: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
        • 10.1.1.3.4 United States: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
      • 10.1.1.4 Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.4.1 Overview
      • 10.1.1.5 Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.5.1 Canada: Infectious Disease Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.5.2 Canada: Infectious Disease Therapeutics Market Breakdown, by Indication
        • 10.1.1.5.3 Canada: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
        • 10.1.1.5.4 Canada: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
      • 10.1.1.6 Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.6.1 Overview
      • 10.1.1.7 Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.7.1 Mexico: Infectious Disease Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.7.2 Mexico: Infectious Disease Therapeutics Market Breakdown, by Indication
        • 10.1.1.7.3 Mexico: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
        • 10.1.1.7.4 Mexico: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel

11. Infectious Disease Therapeutics Market-Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies in the Infectious Disease Therapeutics Market
  • 11.3 Inorganic Growth Strategies
    • 11.3.1 Overview
  • 11.4 Organic Growth Strategies
    • 11.4.1 Overview

12. Company Profiles

  • 12.1 Pfizer Inc
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Gilead Sciences Inc
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 F. Hoffmann-La Roche Ltd
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Shionogi & Co Ltd
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Bayer AG
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 BioCryst Pharmaceuticals Inc
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 GSK Plc
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 AbbVie Inc
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 Merck & Co Inc
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments
  • 12.10 Astellas Pharma Inc
    • 12.10.1 Key Facts
    • 12.10.2 Business Description
    • 12.10.3 Products and Services
    • 12.10.4 Financial Overview
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners

List Of Tables

  • Table 1. North America Infectious Disease Therapeutics Market Segmentation
  • Table 2. Diseases and Funding
  • Table 3. North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Drug Class
  • Table 4. North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Indication
  • Table 5. North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
  • Table 6. North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
  • Table 7. North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Country
  • Table 8. United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
  • Table 9. United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
  • Table 10. United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 11. United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 12. Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
  • Table 13. Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
  • Table 14. Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 15. Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 16. Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
  • Table 17. Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
  • Table 18. Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 19. Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 20. Recent Inorganic Growth Strategies in the Infectious Disease Therapeutics Market
  • Table 21. Recent Organic Growth Strategies in the Infectious Disease Therapeutics Market

List Of Figures

  • Figure 1. North America Infectious Disease Therapeutics Market Segmentation, by Country
  • Figure 2. Impact Analysis of Drivers and Restraints
  • Figure 3. North America Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030
  • Figure 4. North America Infectious Disease Therapeutics Market Share (%) - by Drug Class (2022 and 2030)
  • Figure 5. Anti-viral: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 6. Anti-bacterial: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 7. Anti-fungal: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. North America Infectious Disease Therapeutics Market Share (%) - by Indication (2022 and 2030)
  • Figure 10. HIV: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 11. Hepatitis: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. Tuberculosis: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Influenza: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 14. HPV: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 15. Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 16. North America Infectious Disease Therapeutics Market Share (%) - by Route Of Administration (2022 and 2030)
  • Figure 17. Oral: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 18. Parenteral: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 19. Topical: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 20. Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 21. North America Infectious Disease Therapeutics Market Share (%) - by Distribution Channel (2022 and 2030)
  • Figure 22. Hospital Pharmacies: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 23. Retail Pharmacies: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 24. Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 25. North America Infectious Disease Therapeutics Market, by Key Country - Revenue (2022) (US$ Million)
  • Figure 26. North America Infectious Disease Therapeutics Market Breakdown, by Key Countries, 2022 and 2030 (%)
  • Figure 27. United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 28. Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 29. Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 30. Growth Strategies in the Infectious Disease Therapeutics Market